Skip to main content
Clinical Trials/KCT0006508
KCT0006508
Not yet recruiting
未知

Integrated pharmaceutical care service model using personalized mobile applications for patients with rheumatoid arthritis

Daegu Catholic University Medical Center0 sites282 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Daegu Catholic University Medical Center
Enrollment
282
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional Study
Sex
All

Investigators

Sponsor
Daegu Catholic University Medical Center

Eligibility Criteria

Inclusion Criteria

  • 1\) Among outpatients 18 years of age or older who visit the Department of Rheumatology at Daegu Catholic University Hospital, those who have been diagnosed with rheumatoid arthritis and have received one or more of the following DMARDs
  • \- Conventional DMARDs: Hydroxychloroquine, methotrexate, sulfasalazine, bucillamine, leflunomide, tacrolimus
  • \- Biologic DMARDs (subcutaneous): etanercept, adalimumab, golimumab, tocilizumab, abatacept
  • \- JAK inhibitor: tofacitinib, baricitinb, upadacitinib
  • 2\) Patients who started taking a new drug (DMARD, steroid, or analgesic) at the time of randomization
  • 3\) Persons with mobile devices (smartphones, etc.)
  • 4\) Patients who agreed to participate in the study

Exclusion Criteria

  • 1\) Patients who have difficulty responding to written or interview questionnaires due to cognitive impairment, etc.
  • 2\) Patients with severe systemic or malignant disease
  • 3\) Patients who do not agree to install the medication guide tool (an application or app developed in this study) on the mobile device
  • 4\) Patients who do not agree to provide medication information using Multimedia Messaging Service (MMS)
  • 5\) Patients judged by other researchers as inappropriate to participate in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials